Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Efficacia e tollerabilità di un laser frazionato ibrido per il trattamento delle cicatrici da acne in pazienti con pelle di colore

29 settembre 2026 aggiornato da: Montefiore Medical Center

The investigators aim to investigate the efficacy and tolerability of a hybrid non-ablative/ablative laser for acne scarring in skin of color.

Panoramica dello studio

Descrizione dettagliata

Acne is chronic inflammatory condition involving the pilosebaceous unit. One of the most common complications of acne is scarring, which occurs as a result of dermal damage during the healing process of active acne. Studies have shown that acne scarring can have a negative impact on an individual's quality of life and has been described as a risk factor for multiple psychiatric conditions including depression, anxiety, suicide, and poor self-esteem. Unfortunately, treatment of acne scarring, particularly those of the atrophic subtype, prove difficult to treat. A 2016 Cochrane review failed to provide sufficient evidence to support the first-line use of any intervention. Laser technology has been emerging as an effective, non-invasive treatment of acne scarring. Ablative lasers work by delivering energy to the dermal layer of the skin, resulting in thermal injury and stimulation of dermal cells to produce collagen, thus resolving the scar. More recently, fractional lasers, which create multiple tiny columns of thermal injury, have been introduced with the benefit of reduced downtime and adverse effects compared to ablative lasers. The fractional CO2 laser is widely used for the treatment of acne scarring, however its use is limited in patients of Fitzpatrick IV and V skin due to risk of hyperpigmentation among other adverse events. The erbium-YAG fractional laser serves as an alternative, and has shown to produce less thermal injury and thus be more well-tolerated with lower risk of adverse effects in patients. The hybrid fractional laser combines a 2940 nm wavelength with a 1470 wavelength and has an ablative component targeting the epidermis and a nonablative component targeting the dermis at the same spot. The investigators seek to investigate the Sciton Halo, hybrid fractional laser for its efficacy in treating acne scarring and tolerability in patients with a specific emphasis on those with Fitzpatrick IV and V skin.

Tipo di studio

Interventistico

Iscrizione (Stimato)

50

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • New York
      • Elmsford, New York, Stati Uniti, 10523
        • Reclutamento
        • 555 Taxter Road
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Healthy males and females, ≥ 18 years of age at time of informed consent, seeking treatment for acne scarring
  • Subject must voluntarily sign and date an IRB approved informed consent form
  • Subjects with diagnosis of acne scarring recorded over the past 6 months
  • Able to read, understand and voluntarily provide written informed consent.
  • Subject is determined to be healthy, non-smoker
  • Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements.
  • Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period.

Exclusion Criteria:

  • Subjects does not have the capacity to consent to the study
  • Subject underwent any acne scar treatments in the past 6 months prior to enrollment in the study
  • Subject has active papulopustular or cystic acne within the past 6 months
  • Any history of keloidal scarring
  • Any previous surgical procedure in the treatment area in the past 12 months, or major surgery in the last 6 months
  • History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection), and/or any history of systemic chemotherapy for prior 12 months
  • Subject has no health contraindications to receiving local lidocaine and epinephrine injections, including but not limited to any form of heart disease or arrhythmia, untreated or uncontrolled severe hypertension, uncontrolled hyperthyroidism, uncontrolled diabetes, pheochromocytoma, cocaine use
  • History or current use of the following prescription medications:

Immunosuppressive medications/biologics, 6 months prior to and during the study.

Accutane or other systemic retinoids within the past twelve months TCA, MAO, or beta-blockers

  • Smoking or vaping in the past 12 months
  • History of photosensitivity and/or connective tissue disease
  • History of hyperlipidemia, diabetes mellitus, hepatitis, or bleeding disorders
  • History of major depressive disorders or endocrine disorders including but not limited to; hypothyroidism, Hashimoto's thyroiditis, or hyperthyroidism
  • History of ongoing pregnancy, active breastfeeding, cancer, and epilepsy

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Hybrid Fractional laser - SOC

23 participants with fitzpatrick skin type IV-V will be in this arm. At the first visit, participants will undergo informed consent, education about the procedure, education about proper sun-care, and will be provided sunscreen. Participants will be prescribed a prescription of hydroquinone or a retinol to prevent hyperpigmentation, per standard of care. If participants choose to take this they will wait one month of taking the prescription and then begin treatment sessions. If not, participants can begin treatment sessions right away. Treatment consists of 3 laser sessions with the Sciton Halo hybrid fractional laser. Session amount depends on the degree of improvement. At each session before and after images will be collected. At each session participants will fill out the dermatology quality of life survey as well as a patient satisfaction survey.

Laser treatment

Altri nomi:
  • Laser frazionato ibrido Sciton
  • laser frazionario ibrido
  • Numero di serie: 88086862
Sperimentale: Hybrid Fractional laser- Non- SOC

23 participants with Fitzpatrick skin type I-III will be in this arm. At the first visit, participants will undergo informed consent, education about the procedure, education about proper sun-care, and will be provided sunscreen. Participants will be prescribed a prescription of hydroquinone or a retinol to prevent hyperpigmentation, per standard of care. If participants choose to take this they will wait one month of taking the prescription and then begin treatment sessions. If not, participants can begin treatment sessions right away. Treatment consists of 3 laser sessions with the Sciton Halo hybrid fractional laser. Session amount depends on the degree of improvement. At each session before and after images will be collected. At each session participants will fill out the dermatology quality of life survey as well as a patient satisfaction survey.

Laser treatment

Altri nomi:
  • Laser frazionato ibrido Sciton
  • laser frazionario ibrido
  • Numero di serie: 88086862

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Acne Scar Severity
Lasso di tempo: Baseline to Month 9

Change in acne scarring severity from baseline to nine months will be assessed using the Global Scale for Acne Scar Severity (SCAR-S) scale. The SCAR-S is a validated scale used to assess the severity of acne scarring using a 6-point scale ranging from 0 ("Clear, no visible scars from acne") to 5 ("Very Severe; entire area with prominent atrophic or hypertrophic scars") such that higher scores are indicative of more severe scarring. Two independent blinded dermatologists will rate before and after treatment images using the SCAR-S scale. Results will be summarized by study arm using descriptive statistics.

Baseline to Month 9
Change in Clinician Graded Global Assessment of Improvement Scale (GAIS) score
Lasso di tempo: Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Change in aesthetic success from baseline will be evaluated using the Clinician's Global Assessment of Improvement Scale (CGAIS). The CGAIS evaluates overall efficacy and cosmetic outcomes of the treatment. The CGAIS is based upon a 7-point scale ranging from -3 ("Greatly worsened") to +3 ("Greatly improved"), with 0 ("No change") as the midpoint. Two independent unbiased blinded dermatologists will conduct live/photographic assessments to evaluate patients at baseline, Month 2, Month 3, Month 4, Month 6, and Month 9. Results will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Overall Patient Satisfaction
Lasso di tempo: Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Overall patient satisfaction will be assessed throughout the study using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. This question asks patients to select the option that better represents the change in how their skin looks using a 7-point scale ranging from -3 ("Greatly decreased") to +3 ("Greatly increased"), with 0 ("No change") as the midpoint. Scores will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Patient Assessment of Acne Scarring
Lasso di tempo: Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patient assessment of acne scarring will be assessed throughout the study using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. This question asks patients to select the option that better represents the change in acne scarring in the area treated using a 7-point scale ranging from -3 ("Greatly decreased") to +3 ("Greatly increased"), with 0 ("No change") as the midpoint. Scores will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Patient Assessment of Skin Texture
Lasso di tempo: Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patient assessment of skin texture will be assessed throughout the study using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. This question asks patients to select the option that better represents the change in their skin texture using a 7-point scale ranging from -3 ("Greatly improved") to +3 ("Greatly worsened"), with 0 ("No change") as the midpoint. Scores will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Patient Assessment of Skin Pigmentation
Lasso di tempo: Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patient assessment of skin pigmentation will be assessed throughout the study using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. This question asks patients to select the option that better represents the change in their skin pigmentation using a 7-point scale ranging from -3 ("Greatly improved") to +3 ("Greatly worsened"), with 0 ("No change") as the midpoint. Scores will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Patient Assessment of General Skin Changes - Binary
Lasso di tempo: Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patient assessment of general skin changes will be assessed throughout the study using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. This question asks patients "beyond texture, pigmentation, and overall acne scarring, did you notice any other changes in the area that was treated." Patients will select either "Yes" or "No." Binary responses will be summarized by study arm.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Patient Assessment of General Skin Changes - Categorical
Lasso di tempo: Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patients who confirmed that they did notice changes in the "Patient Assessment of General Skin Changes - Binary" query on the PSQ will be asked to specify what those changes were from a menu of options. These options are "Pores are smaller," "Skin is less oily," "Skin is smoother," "Skin feels better," "Skin looks more radiant," "Face feels more youthful," and "Other." Patients will have the option of selecting more than one response. Responses will be categorically summarized by study arm.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Patient Satisfaction with Treatment
Lasso di tempo: Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patient satisfaction with treatment will be assessed throughout the study using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. This question asks patients how they would characterize their satisfaction with the treatment using the following suite of options: "Very dissatisfied," "Dissatisfied," "Slightly dissatisfied," "Neither Satisfied or Dissatisfied," "Slightly satisfied," "Satisfied," or "Very Satisfied." Ordinal responses will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Recommend Treatment to Family and Friends
Lasso di tempo: Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patients will be asked whether they would recommend the treatment to friends and family members using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. Binary ("Yes" or "No") responses of recommendations to family/friends will be summarized by study arm.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Patient adherence to skin care accommodations for laser treatment
Lasso di tempo: Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patients will be asked whether they are following skin care accommodations for laser treatment using an item from the Patient Satisfaction Questionnaire (PSQ) completed during each visit. Binary ("Yes" or "No") responses of adherence to skin care accommodations for laser treatment will be summarized by study arm.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Daily mineral sunscreen use
Lasso di tempo: Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patients will be asked whether they are using daily mineral sunscreen of SPF30 or greater on the Patient Satisfaction Questionnaire (PSQ) completed during each visit. Binary ("Yes" or "No") responses of usage will be summarized by study arm.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Sun avoidance
Lasso di tempo: Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Patients will be asked whether they are avoiding the sun on the Patient Satisfaction Questionnaire (PSQ) completed during each visit. Binary ("Yes" or "No") responses of sun avoidance will be summarized by study arm.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Treatment-related Side Effects
Lasso di tempo: Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

One of the safety variables will be treatment-related side effects. Patients will be asked whether they are experienced any of the following side effects following laser treatment: "Erythema," "Prolonged erythema," "Acne flare up," "Hypopigmentation," and "Hyperpigmentation." on the Patient Satisfaction Questionnaire (PSQ) completed during each visit. Patients can select any/all treatment-related side effects which they experienced. Responses will be categorically summarized by study arm.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9
Pain Discomfort
Lasso di tempo: Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

One of the safety variables will be pain discomfort. Patients will be asked to quantify the degree of pain discomfort experienced following treatment using a pain scale item provided on the Patient Satisfaction Questionnaire (PSQ) completed during each visit. Patients will rate their pain discomfort on an 11-point Likert scale ranging from 0 ("No Pain") to 10 ("Worst Possible Pain"), such that higher scores are indicative of increased pain discomfort. Results will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Dermatology Quality of Life
Lasso di tempo: Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Dermatology quality of life will be assessed using the Dermatology Life Quality Index (DLQI). The DLQI is a standardized 10-item dermatology scale which determines how much impact a skin condition has had on life quality. Patients are asked to consider how much their skin problem has affected their life over the prior week when responding to each question. Questions are subjectively answered by patients using the following choices: "Very much" (= 3 points), "A lot" (= 2 points), "A little" (= 1 point), and "Not at all" or "Not relevant" (= 0 points). Scores are summarized for an overall possible range of 0-30, such that higher scores are indicative of greater dermatology-related life quality impairment. Results will be summarized by study arm using descriptive statistics.

Baseline to Month 2, Month 3, Month 4, Month 6, and Month 9

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Investigatori

  • Investigatore principale: Kseniya Kobets, MD, Montefiore Medical Center

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

11 ottobre 2023

Completamento primario (Stimato)

1 luglio 2029

Completamento dello studio (Stimato)

1 luglio 2029

Date di iscrizione allo studio

Primo inviato

18 aprile 2022

Primo inviato che soddisfa i criteri di controllo qualità

4 maggio 2022

Primo Inserito (Effettivo)

5 maggio 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

1 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

29 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

No individual participant data will not be available to researchers not part of the original research team. All patient data will be de-identified.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi